Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment
详细信息 查看全文
- 作者：Franca Marino (1)
Andrea Maria Maresca (1)
Marco Cosentino (1)
Luana Castiglioni (1)
Emanuela Rasini (1)
Christian Mongiardi (1)
Ramona C Maio (1)
Massimiliano Legnaro (1)
Laura Schembri (1)
Francesco Dentali (1)
Anna Maria Grandi (1)
Luigina Guasti (1) - 关键词：Type 2 Diabetes ; Angiotensin II type 1 receptor ; Angiotensin II type 2 receptor ; Monocytes ; Statin
- 刊名：Cardiovascular Diabetology
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：11
- 期：1
- 全文大小：170KB
- 参考文献：1. Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. / J Am Coll Cardiol 2007, 49:2129-138. CrossRef
2. Tedgui A, Mallat Z: Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways. / Physiol Rev 2006, 86:515-81. CrossRef
3. Mogi M, Iwai M, Horiuchi M: Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. / Arterioscler Thromb Vasc Biol 2007, 27:2532-539. CrossRef
4. Petnehazy T, Stokes KY, Wood KC, Russell J, Granger DN: Role of Blood Cell–Associated AT1 Receptors in the Microvascular Responses to Hypercholesterolemia. / Arterioscler Thromb Vasc Biol 2006, 26:313-18. CrossRef
5. Tone A, Shikata K, Ogawa D, Sasaki S, Nagase R, Sasaki M, Yozai K, Usui HK, Okada S, Wada J, Shikata Y, Makino H: hanges of gene expression profiles in macrophages stimulated by angiotensin II-angiotensin II induces MCP-2 through AT1-receptor. / J Renin Angiotensin Aldosterone Syst 2007, 8:45-0. CrossRef
6. Savoia C, Touyz RM, Volpe M, Schiffrin EL: Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients. / Hypertension 2007, 49:341-46. CrossRef
7. Hernandez Schulman I, Zhou MS, Raij L: Cross-Talk Between Angiotensin II Receptor Types 1 and 2. / Hypertension 2007,49(Hernandez Schulman I, Zhou MS, Raij L):270-71.
8. Carey RM: Cardiovascular and Renal Regulation by the Angiotensin Type 2 Receptor. The AT2 Receptor Comes of Age. / Hypertension 2005, 45:840-44. CrossRef
9. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. / Lancet 2008, 371:117-25. CrossRef
10. Arora M, Chen L, Paglia M, Gallagher I, Allen JE, Vyas YM, Ray A, Ray P: Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. / Proc Natl Acad Sci USA 2006, 103:7777-782. CrossRef
11. Westerink J, Visseren FLJ: Pharmacological and non pharmacological interventions to influence adipose tissue function. / Cardiovasc Diabetol 2011, 10:13. CrossRef
12. Marino F, Guasti L, Cosentino M, Ferrari M, Rasini E, Maio RC, Cimpanelli MG, Cereda E, Crespi C, Simoni C, Restelli D, Venco A, Lecchini S: Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. / J Cardiovasc Pharmacol 2007, 49:299-05. CrossRef
13. Osterud B, Bjorklid E: Role of monocytes in atherogenesis. / Physiol Rev 2003, 83:1069-112.
14. Giunti S, Calkin AC, Forbes JM, Allen TJ, Thomas MC, Cooper ME, Jandeleit-Dahm KA: The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. / Am J Physiol Renal Physiol 2010, 299:F528-F535. CrossRef
15. Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G: Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. / Am J Physiol Renal Physiol 2010, 299:F1203-F1211. CrossRef
16. Zadelaar S, Kleemann R, Verschuren L, De Vries-Van Der Weij J, Van der Hoorn J, Princen HM, Kooistra T: Mouse Models for Atherosclerosis and Pharmaceutical Modifiers. / Arterioscler Thromb Vasc Biol 2007, 27:1706-721. CrossRef
17. Marino F, Guasti L, Cosentino M, Rasini E, Ferrari M, Maio RC, Loraschi A, Cimpanelli MG, Schembri L, Legnaro M, Molteni E, Crespi C, Crema F, Venco A, Lecchini S: Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. / J Hypertens 2008, 26:1147-155. CrossRef
18. Guasti L, Marino F, Cosentino M, Cimpanelli M, Maio RC, Klersy C, Crespi C, Restelli D, Simoni C, Franzetti I, Gaudio G, Marnini P, Grandi AM, Lecchini S, Venco A: Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. / J Hypertens 2006, 24:2423-430. CrossRef
19. Guasti L, Marino F, Cosentino M, Maio RC, Rasini E, Ferrari M, Castiglioni L, Klersy C, Gaudio G, Grandi AM, Lecchini S, Venco A: Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. / Eur Heart J 2008,29(9):1118-126. CrossRef
20. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: For the Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. / N Engl J Med 1994, 330:877-84. CrossRef
21. Rasini E, Cosentino M, Marino F, Legnaro M, Ferrari M, Guasti L, Venco A, Lecchini S: Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. / Regul Pept 2006, 134:69-4. CrossRef
22. Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. / J Am Coll Cardiol 2006, 47:1093-100. CrossRef
23. Lafuente N, Matesanz N, Azcutia V, Romacho T, Nevado J, Rodríguez-Ma?as L, Moncada S, Peiró C, Sánchez-Ferrer CF: The deleterious effect of high concentrations of D-glucose requires pro-inflammatory preconditioning. / J Hypertens 2008, 26:478-85. CrossRef
24. Liang CP, Han S, Senokuchi T, Tall AR: The Macrophage at the Crossroads of Insulin Resistance and Atherosclerosis. / Circ Res 2007, 100:1546-555. CrossRef
25. Ihara Y, Egashira K, Nakano K, Ohtani K, Kubo M, Koga J, Iwai M, Horiuchi M, Gang Z, Yamagishi S, Sunagawa K: Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. / J Mol Cell Cardiol 2007, 43:455-64. CrossRef
26. Reuter H, Adam C, Gr?nke S, Zobel C, Frank KF, Müller-Ehmsen J, Brabender J, Schwinger RH: The increased angiotensin II (type 1) receptor density in myocardium of type 2 diabetic patients is prevented by blockade of the renin-angiotensin system. / Diabetologia 2006, 49:3067-074. CrossRef
27. Hodroj W, Legedz L, Foudi N, Cerutti C, Bourdillon MC, Feugier P, Beylot M, Randon J, Bricca G: Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. / Arterioscler Thromb Vasc Biol 2007, 27:525-31. CrossRef
28. Carey RM: Angiotensin Receptors and Aging. / Hypertension 2007, 50:33-4. CrossRef
29. Van de Wal RM, van der Harst P, Wagenaar LJ, Wassmann S, Morshuis WJ, Nickenig G, Buikema H, Plokker HW, van Veldhuisen DJ, van Gilst WH, Voors AA: Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease. / J Cardiovasc Pharmacol 2007, 50:372-79. CrossRef
30. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH: Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. / Circulation 2004, 109:2296-301. CrossRef
31. Link A, Ayadhi T, B?hm M, Nickenig G: Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. / Eur Heart J 2006, 27:2945-955. CrossRef
32. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic. / Arterioscler Thromb Vasc Biol 2002, 22:1194-199. CrossRef
33. Devaraj S, Chan E, Jialal I: Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. / J Clin Endocrinol Metab 2006, 91:4489-496. CrossRef
34. Coward W, Chow SC: Effect of atorvastatin on Th1 and Th2 cytokine secreting cells during T cell activation and differentiation. / Atherosclerosis 2006, 186:302-09. CrossRef - 作者单位：Franca Marino (1)
Andrea Maria Maresca (1)
Marco Cosentino (1)
Luana Castiglioni (1)
Emanuela Rasini (1)
Christian Mongiardi (1)
Ramona C Maio (1)
Massimiliano Legnaro (1)
Laura Schembri (1)
Francesco Dentali (1)
Anna Maria Grandi (1)
Luigina Guasti (1)
1. Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
文摘
Background In diabetes, a variety of pro-inflammatory cellular changes has been found in various cell types, including monocytes which are known to be involved in all the phases of atherogenesis. Angiotensin II (Ang II) type 1 receptor (AT1R) mediates the pro-atherogenic effects of Ang II whereas the type 2 receptor (AT2R) seems associated with atheroprotection. We sought to investigate the potential changes of AT1R-AT2R expression in human monocytes of type 2 diabetic- hypercholesterolemic patients and in hypercholesterolemic subjects, upon clinical treatment with rosuvastatin. Methods The AT1R membrane protein and mRNA AT1R and AT2R expression in monocytes were investigated in 10 type 2 diabetic-hypercholesterolemic patients and in 10 hypercholesterolemic subjects, before and after 3-month rosuvastatin treatment. Moreover, the serum cytokine levels of interferon-γ (IFN-γ) and interleukin-4 (IL-4) were detected. Results As expected, rosuvastatin was associated with a change in the lipid profile in the two groups. Both the membrane protein (P--.008) and the AT1R mRNA expression (P--.038) were significantly reduced during treatment in the absence of AT2R expression change in diabetic-hypercholesterolemic patients whereas no significant difference was observed in hypercholesterolemic subjects. The serum IL-4 levels were increased during treatment whereas no change was observed in IFN-γ in diabetic-hypercholesterolemic patients. No cytokine change was observed in hypercholesterolemic subjects. Conclusions Our study on monocytes of diabetic-hypercholesterolemic patients, showing a reduced AT1R but not AT2R expression during rosuvastatin treatment, suggests that statin therapy may modulate favorably the AT1-AT2 receptor balance in subjects with coexistent type 2 diabetes.